The 3 Best Biotech Stocks of 2017
Biotech stocks rocked in 2017. At least a lot of them did. The SPDR S&P Biotech ETF has chalked up a gain of 40% with only a couple of weeks left in the year -- twice the return of the S&P 500 index.
But which biotech stocks performed best of all? Excluding biotechs with tiny market caps below $200 million, three stocks take the top honors for the year: Sangamo Therapeutics (NASDAQ: SGMO), XOMA Corporation (NASDAQ: XOMA), and Marinus Pharmaceuticals (NASDAQ: MRNS). Here's what made 2017 such a fantastic year for these biotech stocks.
Image source: Getty Images.
Source: Fool.com
Nektar Therapeutics Stock
€1.09
-5.290%
Currently there is a rather positive sentiment for Nektar Therapeutics with 4 Buy predictions and 1 Sell predictions.
With a target price of 2 € there is a hugely positive potential of 84.33% for Nektar Therapeutics compared to the current price of 1.09 €.
